Characterisation of male breast cancer: a descriptive biomarker study from a large patient series

M. P. Humphries, S. Sundara Rajan, H. Honarpisheh, G. Cserni, J. Dent, L. Fulford, L. B. Jordan, J. L. Jones, R. Kanthan, M. Litwiniuk, A. Di Benedetto, M. Mottolese, E. Provenzano, S. Shousha, M. Stephens, J. Kulka, I. O. Ellis, A. N. Titloye, A. M. Hanby, A. M. Shaaban & 1 others V. Speirs

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERalpha, ERbeta1, ERbeta2, ERbeta5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases were predominantly ERalpha (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity negatively impacted DFS (p = 0.04). FOXA1 p = 0.005) and AR p = 0.009) were both positively prognostic for DFS, remaining upon multivariate analysis. Network analysis showed ERalpha, AR and FOXA1 significantly correlated. In summary, the principle phenotype of MBC was luminal A, ductal, grade 2. In ERalpha+ MBC, only AR had prognostic significance, suggesting AR blockade could be employed therapeutically.
Original languageEnglish
Pages (from-to)45293
Number of pages1
JournalScientific Reports
Volume7
DOIs
Publication statusPublished - Mar 28 2017

Fingerprint

Male Breast Neoplasms
Estrogen Receptor alpha
Biomarkers
Disease-Free Survival
Cadherins
Prolactin
Cohort Studies
Multivariate Analysis
Immunohistochemistry
Phenotype
Survival

Cite this

Humphries, M. P., Rajan, S. S., Honarpisheh, H., Cserni, G., Dent, J., Fulford, L., ... Speirs, V. (2017). Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Scientific Reports, 7, 45293. https://doi.org/10.1038/srep45293 [doi]

Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. / Humphries, M. P.; Rajan, S. Sundara; Honarpisheh, H.; Cserni, G.; Dent, J.; Fulford, L.; Jordan, L. B.; Jones, J. L.; Kanthan, R.; Litwiniuk, M.; Benedetto, A. Di; Mottolese, M.; Provenzano, E.; Shousha, S.; Stephens, M.; Kulka, J.; Ellis, I. O.; Titloye, A. N.; Hanby, A. M.; Shaaban, A. M.; Speirs, V.

In: Scientific Reports, Vol. 7, 28.03.2017, p. 45293.

Research output: Contribution to journalArticle

Humphries, MP, Rajan, SS, Honarpisheh, H, Cserni, G, Dent, J, Fulford, L, Jordan, LB, Jones, JL, Kanthan, R, Litwiniuk, M, Benedetto, AD, Mottolese, M, Provenzano, E, Shousha, S, Stephens, M, Kulka, J, Ellis, IO, Titloye, AN, Hanby, AM, Shaaban, AM & Speirs, V 2017, 'Characterisation of male breast cancer: a descriptive biomarker study from a large patient series', Scientific Reports, vol. 7, pp. 45293. https://doi.org/10.1038/srep45293 [doi]
Humphries, M. P. ; Rajan, S. Sundara ; Honarpisheh, H. ; Cserni, G. ; Dent, J. ; Fulford, L. ; Jordan, L. B. ; Jones, J. L. ; Kanthan, R. ; Litwiniuk, M. ; Benedetto, A. Di ; Mottolese, M. ; Provenzano, E. ; Shousha, S. ; Stephens, M. ; Kulka, J. ; Ellis, I. O. ; Titloye, A. N. ; Hanby, A. M. ; Shaaban, A. M. ; Speirs, V. / Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. In: Scientific Reports. 2017 ; Vol. 7. pp. 45293.
@article{12af76e0446145e2ae4c9a4925d953f9,
title = "Characterisation of male breast cancer: a descriptive biomarker study from a large patient series",
abstract = "Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERalpha, ERbeta1, ERbeta2, ERbeta5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81{\%}, 83{\%}), grade 2; (40{\%}, 44{\%}), respectively. Cases were predominantly ERalpha (84{\%}, 82{\%}) and PR positive (74{\%}, 71{\%}), respectively, with HER2 expression being infrequent (2{\%}, 10{\%}), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity negatively impacted DFS (p = 0.04). FOXA1 p = 0.005) and AR p = 0.009) were both positively prognostic for DFS, remaining upon multivariate analysis. Network analysis showed ERalpha, AR and FOXA1 significantly correlated. In summary, the principle phenotype of MBC was luminal A, ductal, grade 2. In ERalpha+ MBC, only AR had prognostic significance, suggesting AR blockade could be employed therapeutically.",
author = "Humphries, {M. P.} and Rajan, {S. Sundara} and H. Honarpisheh and G. Cserni and J. Dent and L. Fulford and Jordan, {L. B.} and Jones, {J. L.} and R. Kanthan and M. Litwiniuk and Benedetto, {A. Di} and M. Mottolese and E. Provenzano and S. Shousha and M. Stephens and J. Kulka and Ellis, {I. O.} and Titloye, {A. N.} and Hanby, {A. M.} and Shaaban, {A. M.} and V. Speirs",
note = "LR: 20170403; JID: 101563288; 2016/10/17 [received]; 2017/02/23 [accepted]; epublish",
year = "2017",
month = "3",
day = "28",
doi = "10.1038/srep45293 [doi]",
language = "English",
volume = "7",
pages = "45293",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Characterisation of male breast cancer: a descriptive biomarker study from a large patient series

AU - Humphries, M. P.

AU - Rajan, S. Sundara

AU - Honarpisheh, H.

AU - Cserni, G.

AU - Dent, J.

AU - Fulford, L.

AU - Jordan, L. B.

AU - Jones, J. L.

AU - Kanthan, R.

AU - Litwiniuk, M.

AU - Benedetto, A. Di

AU - Mottolese, M.

AU - Provenzano, E.

AU - Shousha, S.

AU - Stephens, M.

AU - Kulka, J.

AU - Ellis, I. O.

AU - Titloye, A. N.

AU - Hanby, A. M.

AU - Shaaban, A. M.

AU - Speirs, V.

N1 - LR: 20170403; JID: 101563288; 2016/10/17 [received]; 2017/02/23 [accepted]; epublish

PY - 2017/3/28

Y1 - 2017/3/28

N2 - Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERalpha, ERbeta1, ERbeta2, ERbeta5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases were predominantly ERalpha (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity negatively impacted DFS (p = 0.04). FOXA1 p = 0.005) and AR p = 0.009) were both positively prognostic for DFS, remaining upon multivariate analysis. Network analysis showed ERalpha, AR and FOXA1 significantly correlated. In summary, the principle phenotype of MBC was luminal A, ductal, grade 2. In ERalpha+ MBC, only AR had prognostic significance, suggesting AR blockade could be employed therapeutically.

AB - Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERalpha, ERbeta1, ERbeta2, ERbeta5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases were predominantly ERalpha (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity negatively impacted DFS (p = 0.04). FOXA1 p = 0.005) and AR p = 0.009) were both positively prognostic for DFS, remaining upon multivariate analysis. Network analysis showed ERalpha, AR and FOXA1 significantly correlated. In summary, the principle phenotype of MBC was luminal A, ductal, grade 2. In ERalpha+ MBC, only AR had prognostic significance, suggesting AR blockade could be employed therapeutically.

U2 - 10.1038/srep45293 [doi]

DO - 10.1038/srep45293 [doi]

M3 - Article

VL - 7

SP - 45293

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

ER -